Liberatti 0.02mg/3mg, 28 tablets — Made in Spain — Free Delivery

Product description 

Compound

Contraindications

• Combined hormonal contraceptives (CHCs) should not be used if any of the following conditions are present. If any of these conditions occur for the first time during the use of CHC, the preparation should be stopped immediately.
• the presence or risk of developing venous thromboembolism (VTE);
• the presence or risk of developing arterial thromboembolism (ATE);
• diabetes mellitus with vascular complications;
• severe arterial hypertension;
• severe dyslipoproteinemia;
• the presence of severe liver disease at present or in history, until the indicators of liver function have returned to the normal range;
• severe renal failure or acute renal failure;
• the presence of liver tumors at present or in history (benign or malignant);
• known or suspected malignant tumors (for example, genital or mammary glands), dependent on sex hormones;
• vaginal bleeding of unknown etiology;
• hypersensitivity to the active substances or to any of the components of the preparation;

Mode of application

Application features